Sign up to save your podcasts
Or
Share Long-Term Safety of DMTs: What We Know and What We Need to Know
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Long-Term Safety of DMTs: What We Know and What We Need to Know
Guest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
View all episodes
By ReachMDGuest: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Guest: Ahmed Z. Obeidat, MD, PhD
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.